These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23979195)

  • 21. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 22. Targeting resistance in lung cancer.
    Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718
    [No Abstract]   [Full Text] [Related]  

  • 23. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.
    Morinaga R; Okamoto I; Furuta K; Kawano Y; Sekijima M; Dote K; Satou T; Nishio K; Fukuoka M; Nakagawa K
    Lung Cancer; 2007 Dec; 58(3):411-3. PubMed ID: 17601631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
    Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
    Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
    van Noesel J; van der Ven WH; van Os TA; Kunst PW; Weegenaar J; Reinten RJ; Kancha RK; Duyster J; van Noesel CJ
    J Clin Oncol; 2013 Apr; 31(10):e161-4. PubMed ID: 23358982
    [No Abstract]   [Full Text] [Related]  

  • 26. Review. EGFR mutations in non-small cell lung cancer--clinical implications.
    Charpidou A; Blatza D; Anagnostou V; Syrigos KN
    In Vivo; 2008; 22(4):529-36. PubMed ID: 18712184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
    Masago K; Fujita S; Irisa K; Kim YH; Ichikawa M; Mio T; Mishima M
    Jpn J Clin Oncol; 2010 Nov; 40(11):1105-9. PubMed ID: 20522446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
    Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 31. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 32. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 33. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2007 Nov; 22(6):1-3. PubMed ID: 18080406
    [No Abstract]   [Full Text] [Related]  

  • 34. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
    Gandara DR; Lara PN; Mack P; Scagliotti G
    Clin Lung Cancer; 2009 May; 10(3):148-50. PubMed ID: 19443333
    [No Abstract]   [Full Text] [Related]  

  • 35. Multigene mutation analysis on cytologic samples.
    Fleury-Feith J; Gounant V; Lacave R; Cadranel J; Bernaudin JF
    Chest; 2011 Dec; 140(6):1664. PubMed ID: 22147827
    [No Abstract]   [Full Text] [Related]  

  • 36. Biologic staging of non-small-cell lung cancer: prospect or proposal?
    Barlesi F; Jacot W; Pujol JL
    Clin Lung Cancer; 2005 Jan; 6(4):225-6. PubMed ID: 15694014
    [No Abstract]   [Full Text] [Related]  

  • 37. The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy.
    Sharma J; Shum E; Chau V; Paucar D; Cheng H; Halmos B
    Respiration; 2017; 93(1):1-14. PubMed ID: 27894113
    [No Abstract]   [Full Text] [Related]  

  • 38. [Regional molecular genetics centers in thoracic oncology: what and who should be tested?].
    Barlesi F; Tomasini P; Fina F; Secq V; Greillier L; Nanni-Metellus I; Garcia S; Ouafik L
    Bull Cancer; 2013; 100(7-8):737-41. PubMed ID: 23823903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intronic boundary mutation rs430397 cannot affect alternate splicing and is an indecisive risk factor for non-small cell lung cancer.
    Zhu X; Fan W; Li D
    Chest; 2012 Dec; 142(6):1691-1692. PubMed ID: 23208355
    [No Abstract]   [Full Text] [Related]  

  • 40. Sharing new approaches to translational research in non-small cell lung cancer.
    O'Brate A; Tarón M; Gandara D; Rosell R
    Oncologist; 2000; 5(6):514-9. PubMed ID: 11110605
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.